Clinical Publications and Presentations

Performance of a targeted Methylation-Based Multi-Cancer Early Detection Test By Race/Ethnicity

Daratumumab (DARA) Maintenance Therapy Following DARA + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): End-of-Study Analysis of LYRA

CheckMate 8KX: Phase 1/2 Multitumor Preliminary Analyses of A Subcutaneous Formulation of Nivolumab (± rHuPH20)

Outreach: Preliminary Safety and Efficacy Results From A Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity setting

Preliminary Results of The Phase 2 Study of Zanubrutinib in Patients With Previously Treated B-cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib

Biologically Optimized Schedule of Gemcitabine and Nab-Paclitaxel Regimen in Metastatic Pancreatic Adenocarcinoma

Real-World One-Year Overall Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Treated With Liposomal Irinotecan in the NAPOLI-1 Based Regimen

Novel Approaches to Therapeutics in Pancreatic Adenocarcinoma: Vitamin C and Tumor Treatment Fields

Real-World Outcomes Associated With Liposomal Irinotecan Dose Reductions in Metastatic Pancreatic Ductal Adenocarcinoma.

Altered Gemcitabine and Nab-Paclitaxel Scheduling Improves Therapeutic Efficacy Compared With Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.